VA BENEFITS REFERENCE
DC 7817: Erythroderma
Read VA diagnostic code 7817 for Erythroderma: published criteria, regulatory notes, related codes and official sources checked October 25, 2026.
Published criteria from 38 CFR 4.118, current through 2026-10-22. Historical decisions may require a different version. This reference does not diagnose a condition or determine an evaluation.
The Skin · All Diagnostic Codes
DC 7817: Erythroderma
Diagnostic code 7817 addresses Erythroderma. Read its specific instructions together with any shared formula, notes and linked provisions. These criteria describe evaluation after the applicable entitlement requirements are met; this reference does not diagnose a condition or determine a claim.
| Rating | |
|---|---|
| 7817 Erythroderma: | |
| Generalized involvement of the skin with systemic manifestations (such as fever, weight loss, or hypoproteinemia) AND one of the following | 100 |
| Constant or near-constant systemic therapy such as therapeutic doses of corticosteroids, other immunosuppressive drugs, retinoids, PUVA (psoralen with long-wave ultraviolet-A light), UVB (ultraviolet-B light) treatments, biologics, or electron beam therapy required over the past 12 month period; or | |
| No current treatment due to a documented history of treatment failure with 2 or more treatment regimens | 100 |
| Generalized involvement of the skin without systemic manifestations and one of the following | |
| Constant or near-constant systemic therapy such as therapeutic doses of corticosteroids, other immunosuppressive drugs, retinoids, PUVA, UVB treatments, biologics, or electron beam therapy required over the past 12-month period; or | |
| No current treatment due to a documented history of treatment failure with 1 treatment regimen | 60 |
| Any extent of involvement of the skin, and any of the following therapies required for a total duration of 6 weeks or more, but not constantly, over the past 12-month period: systemic therapy such as therapeutic doses of corticosteroids, other immunosuppressive drugs, retinoids, PUVA, UVB treatments, biologics, or electron beam therapy | 30 |
| Any extent of involvement of the skin, and any of the following therapies required for a total duration of less than 6 weeks over the past 12-month period: systemic therapy such as therapeutic doses of corticosteroids, other immunosuppressive drugs, retinoids, PUVA, UVB treatments, biologics, or electron beam therapy | 10 |
| Any extent of involvement of the skin, and no more than topical therapy required over the past 12-month period | 0 |
| Note: Treatment failure is defined as either disease progression, or less than a 25 percent reduction in the extent and severity of disease after four weeks of prescribed therapy, as documented by medical records |
What The Criteria Measure
- Does the decision identify diagnostic code 7817, and does the medical record describe the condition named by this code?
- Are the required clinical measurements, testing methods and any stated exceptions documented by a qualified clinician?
- Do records identify the treatment, procedure and relevant dates that the provision actually distinguishes?
- Have the code-specific notes and cross-references been read before comparing any listed evaluation?
Related Public DBQs
Editorial subject matches, not official VA code-to-form assignments. Read the form scope and clinician instructions.
Shared Rules And Regulatory Context
Context provisions do not create an additional evaluation automatically assigned to every condition.
Related Guides
Official Sources
Last verified 2026-10-25. Source publication or legal effective dates are shown separately where available.
Check The Source. Get Accredited Help.
Use this resource to understand published information. VA and the official decision control individual benefits.